rs113849804
Variant summary
Our verdict is Benign. Variant got -9 ACMG points: 1P and 10B. PP2BP4BP6BS1BS2
The NM_004329.3(BMPR1A):c.1433G>A(p.Arg478His) variant causes a missense change. The variant allele was found at a frequency of 0.000354 in 1,614,098 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_004329.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -9 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.000237 AC: 36AN: 152204Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.000171 AC: 43AN: 251494Hom.: 0 AF XY: 0.000177 AC XY: 24AN XY: 135922
GnomAD4 exome AF: 0.000367 AC: 536AN: 1461894Hom.: 0 Cov.: 32 AF XY: 0.000352 AC XY: 256AN XY: 727248
GnomAD4 genome AF: 0.000237 AC: 36AN: 152204Hom.: 0 Cov.: 32 AF XY: 0.000175 AC XY: 13AN XY: 74356
ClinVar
Submissions by phenotype
not provided Uncertain:4Benign:1Other:1
In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Observed individuals with breast cancer, colorectal cancer, or other Lynch syndrome-associated tumor (Tung et al., 2015; Yurgelun et al., 2015; DeRycke et al., 2017; Pearlman et al., 2017; Yurgelun et al., 2017; MacFarland et al., 2021); This variant is associated with the following publications: (PMID: 22703879, 28135145, 30374176, 33097490, 25186627, 25980754, 28944238, 27978560, 32522605, 33032550, 25996639, 28873162, 25801821, 30814609) -
- -
Variant interpretted as Uncertain significance and reported on 06-21-2018 by Lab or GTR ID 26957. GenomeConnect assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. GenomeConnect staff make no attempt to reinterpret the clinical significance of the variant. -
- -
BS1 -
- -
not specified Uncertain:2Benign:1
- -
Variant summary: BMPR1A c.1433G>A (p.Arg478His) results in a non-conservative amino acid change located in the Serine-threonine/tyrosine-protein kinase, catalytic domain of the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.00017 in 251494 control chromosomes, predominantly at a frequency of 0.00029 within the Non-Finnish European subpopulation in the gnomAD database. The observed variant frequency within Non-Finnish European control individuals in the gnomAD database is approximately 145 fold of the estimated maximal expected allele frequency for a pathogenic variant in BMPR1A causing Juvenile Polyposis Syndrome phenotype (2e-06). Although c.1433G>A has been reported in the literature within settings of multigene panel testing for hereditary cancers, these report(s) do not provide unequivocal conclusions about association of the variant with Juvenile Polyposis Syndrome (example Yurgelun_2015, Dalessandro_2015, Johnston_2012, Pearlman_2016, Tung_2014, Yurgelun_2017, Tsai_2019). A recent study reporting outcomes of re-classification of VUS from patient-driven family studies reported this variant with no cases of polyposis in a family (Tsai_2019). Co-occurrences with other pathogenic variant(s) have been reported in the literature and at our laboratory (examples, Yurgelun_2015, EPCAM deletion of exons 1-9; Our laboratory, BRCA2 c.1813dupA, p.I1605fs*11; Tsai_2019, an unspecified co-occurrence with a pathogenic variant in the PALB2 gene), providing supporting evidence for a benign role. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 22703879, 25980754, 25186627, 25996639, 27978560, 28135145, 30374176). ClinVar contains an entry for this variant (Variation ID: 41780). Based on the evidence outlined above, the variant was classified as likely benign. -
The p.Arg478His variant in BMPR1A has been reported in 1 individual with suspect ed Lynch Syndrome (Yurgelun 2015), 2 individuals who underwent exome sequencing for non-cancer related indications (Johnston 2012, D'Alessandro 2016) and has al so been reported in ClinVar (Variation ID 41780). This variant has also been ide ntified in 15/66738 of European chromosomes by the Exome Aggregation Consortium (ExAC, http://exac.broadinstitute.org; dbSNP rs113849804). Computational predict ion tools and conservation analysis suggest that the p.Arg478His variant may not impact the protein, though this information is not predictive enough to rule ou t pathogenicity. In summary, the clinical significance of the p.Arg478His varian t is uncertain. -
Hereditary cancer-predisposing syndrome Benign:3
- -
This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
- -
Generalized juvenile polyposis/juvenile polyposis coli Uncertain:1Benign:1
The BMPR1A variant designated as NM_004329.2:c.1433G>A (p.Arg478His) is classified as likely benign. This variant is listed in population databases and is found in approximately 1 out of 1750 individuals of European ancestry. In silico programs predict that this variant is likely to be tolerated (SIFT, Polyphen-2, Align-GVGD). In one observed family, this variant was not shown to segregate with colon polyps in family members who were over 60 years old. Bayesian analysis integrating all of this data (Tavtigian et al, 2018, PMID:29300386) gives approimately 1% probability of pathogenicity, which is consistent with a classification of likely benign. This variant is not predicted to alter BMPR1A function or modify cancer risk. A modest (less than 2 fold) increase in cancer risk due to this variant cannot be entirely excluded. This analysis was performed in conjunction with the family studies project as part of the University of Washington Find My Variant Study. -
- -
Juvenile polyposis syndrome Benign:2
This variant is considered likely benign. Homozygosity has been confirmed in one or more individuals. As homozygosity for pathogenic variants in this gene is generally assumed to result in embryonic lethality, this variant is unlikely to be pathogenic. -
- -
Polyposis syndrome, hereditary mixed, 2;C1868081:Generalized juvenile polyposis/juvenile polyposis coli Uncertain:1
- -
BMPR1A-related disorder Uncertain:1
The BMPR1A c.1433G>A variant is predicted to result in the amino acid substitution p.Arg478His. This variant has been identified in an individual from a study of participants who were selected for a range of atherosclerosis phenotypes, but not for a personal or family history of cancer (Johnston et al. 2012. PubMed ID: 22703879). Additionally, it was identified in an individual with atrioventricular septum defect who also had learning and psychiatric disabilities and cervical spine anomalies (D'Alessandro et al. 2016. PubMed ID: 25996639). Multiple studies identified this variant in individuals with colorectal cancer and classified it as a variant of uncertain significance (Table S2, Yurgelun et al. 2015. PubMed ID: 25980754; eTable 2, Pearlman et al. 2017. PubMed ID: 27978560). This variant is reported in 0.029% of alleles in individuals of European (Non-Finnish) descent in gnomAD and has conflicting interpretations ranging from benign to uncertain significance in ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/variation/41780/). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at